Why research peptides contain 'strange' amino acids

A D before an amino acid, a doubly-methylated tyrosine, a shielded terminus: design choices rather than errors, and what they do for stability and selectivity.

Peptalis: for laboratory research use only. Not for human use.

Michel van der Veen · Registered Nurse · Science Editor, Peptalis · Basics

Read the structure line of a research peptide and something strange soon appears. A “D” standing before an amino acid. A tyrosine with two extra methyl groups attached. Or a terminus sealed off with a small chemical group instead of left open. These are not typos and not impurities. They are design choices.

Researchers deliberately modify the building blocks of a peptide, and the reason is always the same: an ordinary peptide is broken down quickly in the body, and a researcher who wants to keep the molecule intact long enough to measure anything has to slow that breakdown without losing the activity. The tricks that do this explain much of what looks “strange” about a sequence.

The standard alphabet and its limits

Proteins and peptides are built from amino acids, and the body works by default with an alphabet of twenty of them. Each amino acid exists in principle in two mirror-image forms, labelled L and D, like a left and a right hand that mirror each other but are not identical. Almost all life on earth uses only the L form.

That comes at a price. The enzymes that break peptides down, the proteases, evolved to recognise precisely those L building blocks and to cut the chains between them. A peptide made entirely of ordinary L amino acids is therefore an easy target. In blood or tissue it can be broken down within minutes to a few hours. For research that is awkward: a molecule that disappears too fast is hard to study.

D-amino acids: mirror images enzymes do not recognise

The first intervention follows logically from the above. Replace an L amino acid with its D mirror image, and the cutting enzyme no longer recognises the site well. The chain becomes harder to break at that point, and the peptide stays intact longer.

An example is in our database. SS-31, a mitochondria-targeted tetrapeptide, begins with a D-arginine (D-Arg), the mirror-image form of ordinary arginine. That choice contributes to the stability of the molecule. It is no coincidence that a compound meant to accumulate in a specific cell component is built from blocks that are not immediately snipped.

The nuance matters: a single D amino acid does not automatically make a peptide indestructible, and it does not generalise to every peptide. It is a targeted intervention at a vulnerable spot, not a blanket guarantee.

Schematic: the same building block in L- and D-form. The cleaving enzyme recognises the natural L-form but not the D mirror image, so the D-form stays intact longer. Simplified depiction, not a spatial structure.

Modified side chains: Dmt as an example

Besides inverting an amino acid, its side chain can be altered. Alongside D-Arg, SS-31 contains Dmt, short for 2′,6′-dimethyltyrosine: a tyrosine with two extra methyl groups attached. That is not an amino acid the body itself uses. It is non-proteinogenic, meaning it does not belong to the standard alphabet of twenty.

Such altered side chains serve two purposes at once. They can, like the D form, slow breakdown. And they can fine-tune the way the molecule binds: how precisely and how firmly it engages its target. A molecule with a tailored side chain can be more selective than its natural counterpart.

Semax · stability by design Claim boundary: the molecular route (Pro-Gly-Pro stabilisation, transport) is well grounded chemically. The BDNF/plasticity route is mostly studied in animal models; human data exists but is limited.The added Pro-Gly-Pro tail shields the vulnerable fragment, an example of stability by design.

Shielding the termini: the beginning and end of the chain

A peptide chain has two ends, and those ends are favourite attack points for certain enzymes that nibble the chain from the outside. By shielding an end, for example with a small acetyl group at the start (acetylation) or an amide group at the finish (amidation), that attack point is removed.

There are examples of this in the database too. Semax is a peptide whose stability rests partly on such interventions to the chain, and in BPC-157 the presence of proline (an amino acid with an unusual, rigid ring structure) plays a role in how well the molecule keeps its shape and coherence. Different tricks, the same goal: keeping the molecule intact long enough to do meaningful research on it.

BPC-157 · proline and structural stability Three consecutive prolines (positions 3–5) give the chain a rigid kink that contributes to the molecule's durability.

Why this matters for anyone reading the research

Back to the structure line this article opened with. A “D”, a double methyl group or a shielded terminus is not noise in the data. It is information. It says something about how a molecule was designed and why it behaves differently from the natural variant it is derived from.

That is why we note the chemistry of every compound explicitly: the sequence, the molecular formula, the average molecular weight and the CAS number, verified against public sources. Anyone who learns to read those data sees not only what a compound is, but begins to see why it is built the way it is.

Scientific references

  1. 01Birk AV, et al. J Am Soc Nephrol. 2013;24(8):1250-61. PMID 23813215 · DOI 10.1681/ASN.2012121216
  2. 02Chavez JD, et al. Proc Natl Acad Sci USA. 2020;117(26):15363-15373. PMID 32554501 · DOI 10.1073/pnas.2002250117

Read further

Read the full profile →

Michel van der Veen · Registered Nurse · Science Editor, Peptalis · Sources checked via PubMed · 2 references · educational use only, within the RUO framework · basic peptide-chemistry concepts; SS-31 examples verified, reference date August 2026.

Compounds in this article

For laboratory research use only. Not for human use.